And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest, but is sprinkled with some rather worthy goals. We hope to catch up on some reading, undertake a round of spring cleaning, and indulge our short people. And what about you? As noted, this is a fine time to tidy up your own castle. Perhaps enjoying some time outdoors is in order. You could make a new acquaintance or make time for someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

A sizable proportion of employers support proposals to eliminate the rebates paid by drug makers to win favorable insurance coverage, STAT writes, citing a survey. Specifically, 42% of nearly 600 employers support eliminating rebates for both public and private payers, and another 5% were in favor of eliminating them only for government health care plans. Just 17% opposed any change to the current rebating system, but 36% have no opinion or want more information. However, larger employers were more likely to oppose eliminating rebates.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that “merely” being charged as “a public nuisance” by Oklahoma is certainly ‘damnation by faint praise,’ given the language many in the public sphere are using about pharma’s role in the opiod epidemic?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy